-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD) Drug Details: GSK-5462688 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Prednisone in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prednisone in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prednisone in Asthma Drug Details: Prednisone (ORB-101) is under development for the treatment...
-
Thematic Analysis
Agriculture M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Agriculture Sector.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WVE-006 in Alpha-1 Antitrypsin Deficiency (A1AD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. WVE-006 in Alpha-1 Antitrypsin Deficiency (A1AD) Drug Details: WVE-006 are under development for the treatment...
-
Product Insights
Bronchiolitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bronchiolitis - Drugs In Development, 2023’, provides an overview of the Bronchiolitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchiolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Nephrotic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Nephrotic Syndrome - Drugs In Development, 2023’, provides an overview of the Nephrotic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nasopharyngitis (Common Cold) – Drugs In Development, 2023
Global Markets Direct’s, ‘Nasopharyngitis (Common Cold) - Drugs In Development, 2023’, provides an overview of the Nasopharyngitis (Common Cold) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute Sensorineural Hearing Loss – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Drugs In Development, 2023’, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Bronchitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bronchitis - Drugs In Development, 2023’, provides an overview of the Bronchitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Eosinophilic Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Eosinophilic Esophagitis - Drugs In Development, 2023’, provides an overview of the Eosinophilic Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...